Literature DB >> 3098107

Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.

J H Kinoshita.   

Abstract

In diabetic cataracts aldose reductase initiates the cataractous process by converting glucose to sorbitol. The ensuing osmotic change, caused by sorbitol accumulation, adversely affects the lens permeability barrier so that the distribution within the lens of electrolytes, amino acids, and myo-inositol becomes grossly altered. These changes affect lens viability resulting in opacification. That aldose reductase triggers the process is shown by the fact that several structurally unrelated aldose reductase inhibitors prevent cataracts from occurring. Aldose reductase is also implicated in diabetic retinopathy and keratopathy. Aldose reductase functions in the retinal capillary pericytes, the cells first affected in microvascular abnormalities in diabetes. Additionally, retinal capillary basement membrane thickening can be prevented by aldose reductase inhibitors. Clinical trials are underway to determine the efficacy and safety of aldose reductase inhibitors in treatment of diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3098107     DOI: 10.1016/0002-9394(86)90394-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

Review 1.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

2.  Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.

Authors:  Peter F Kador; Terah R Webb; Dineli Bras; Kerry Ketring; Milton Wyman
Journal:  Vet Ophthalmol       Date:  2010-11       Impact factor: 1.644

3.  Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac.

Authors:  C Marques; J S Ramalho; P Pereira; M C Mota
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

4.  Metabolic cataracts in newly diagnosed diabetes.

Authors:  V Datta; P G Swift; G H Woodruff; R F Harris
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

5.  Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments.

Authors:  A W Stitt; H R Anderson; T A Gardiner; D B Archer
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

6.  Diabetic retinopathy: morphometric analysis of basement membrane thickening of capillaries in different retinal layers within arterial and venous environments.

Authors:  H R Anderson; A W Stitt; T A Gardiner; D B Archer
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

7.  Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs.

Authors:  T A Gardiner; A W Stitt; H R Anderson; D B Archer
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

8.  Diabetic choroidal and iris vasculature scanning electron microscopy findings.

Authors:  A W Fryczkowski; B L Hodes; J Walker
Journal:  Int Ophthalmol       Date:  1989-07       Impact factor: 2.031

9.  A simple and stable galactosemic cataract model for rats.

Authors:  Lixia Ji; Caina Li; Ning Shen; Yi Huan; Quan Liu; Shuainan Liu; Zhufang Shen
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation.

Authors:  Jie Tang; Yunpeng Du; J Mark Petrash; Nader Sheibani; Timothy S Kern
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.